Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

By Tan Jing  

Clinical Rheumatology, Vol. 31, Iss. 8, 2012-08 ,pp. : 1169-1175

Springer Publishing Company

Access to resources Recommend Favorite

Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response

By Sakellariou GT   Sayegh FE   Anastasilakis AD   Bisbinas I   Kapetanos GA  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 5, 2013-10 ,pp. : 369-372

Informa Healthcare

Access to resources Recommend Favorite

Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project

By  

European Neurology, Vol. 65, Iss. 2, 2011-01 ,pp. : 59-67

Karger

Access to resources Recommend Favorite

Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs

By  

Current Rheumatology Reviews, Vol. 13, Iss. 1, 2017-01 ,pp. : 72-78

Bentham Science Publishers

Access to resources Recommend Favorite

Increased Frequency of Mutations in the Gene Responsible for Familial Mediterranean Fever (MEFV) in a Cohort of Patients with Ulcerative Colitis: Evidence for a Potential Disease-Modifying Effect?

By Giaglis Stavros   Mimidis Konstantinos   Papadopoulos Vassilios   Thomopoulos Konstantinos   Sidiropoulos Prodromos   Rafail Stavros   Nikolopoulou Vassiliki   Fragouli Eleni   Kartalis Georgios   Tzioufas Athanasios   Boumpas Dimitrios   Ritis Konstantinos  

Digestive Diseases and Sciences, Vol. 51, Iss. 4, 2006-04 ,pp. : 687-692

Springer Publishing Company

Access to resources Recommend Favorite